Insider · CIK 0001532218
Sanj K Patel
ceochairofficerdirector
Files at KNSA (Kiniksa Pharmaceuticals International, plc). First filing Nov 8, 2024, latest Oct 22, 2025.
Sanj K Patel files SEC Form 4 as CEO, chair and director at KNSA (Kiniksa Pharmaceuticals International, plc). Since Nov 8, 2024, Sanj K Patel has reported 0 open-market buys worth $0 and 6 open-market sells worth $15M, the latest filed on Oct 22, 2025.
A track record needs three past buys with six months of prices behind them; Sanj K Patel has 0, so none is measured yet.
The newest scored trade: sold $10M of KNSA on Oct 20, 2025, filed Oct 22, 2025, scored 50 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $10M.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 6
$0 bought, $15M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
KNSA: Kiniksa Pharmaceuticals International, plc
KNSAOct 9, 2026 · close 79.78
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Kiniksa Pharmaceuticals International, plc | $10M 257,969 shares | -111% | +115% from low0% from high | |
| 50Moderate | Kiniksa Pharmaceuticals International, plc | $2.3M 86,270 shares | -85% | +48% from low-3% from high | |
| 13Weak | Kiniksa Pharmaceuticals International, plc | $63k 2,349 shares | -2% | +47% from low-4% from high | |
| 14Weak | Kiniksa Pharmaceuticals International, plc | $78k 2,872 shares | -3% | +41% from low-8% from high | |
| 17Weak | Kiniksa Pharmaceuticals International, plc | $219k 8,095 shares | -8% | +47% from low-4% from high | |
| 43Moderate | Kiniksa Pharmaceuticals International, plc | $2.1M 89,561 shares | -53% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 7, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | 99,586 0.24% of outstanding | $2.7M | May 7, 2025 | none |
| Nov 6, 2024 | KNSA Kiniksa Pharmaceuticals International, plc | 89,561 0.22% of outstanding | $2.1M | Nov 6, 2024 | none |
Transactions
The newest 50 of 94 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Shareindirect: Held by The Patel Family Irrevocable Trust of 2025 | +9,991 | - | - | 86,165 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Shareindirect: Held by The Patel Family Irrevocable Trust of 2025 | +9,991 | - | - | 86,165 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Shareindirect: Held by The Patel Family Irrevocable Trust of 2025 | +6,481 | - | - | 92,646 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Shareindirect: Held by The Patel Family Irrevocable Trust of 2025 | +6,481 | - | - | 92,646 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Shareindirect: Held by The Patel Family Irrevocable Trust of 2025 | +6,237 | - | - | 98,883 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Shareindirect: Held by The Patel Family Irrevocable Trust of 2025 | +6,237 | - | - | 98,883 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Shareindirect: Held by The Patel Family Irrevocable Trust of 2025 | +8,609 | - | - | 107,492 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Shareindirect: Held by The Patel Family Irrevocable Trust of 2025 | +8,609 | - | - | 107,492 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | FTax withholding Class A Ordinary Shareindirect: Held by The Patel Family Irrevocable Trust of 2025 | -15,144 | $79.28 | $1.2M | 92,348 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | FTax withholding Class A Ordinary Shareindirect: Held by The Patel Family Irrevocable Trust of 2025 | -15,144 | $79.28 | $1.2M | 92,348 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | AGrant or award Restricted Share Unitderivative | +30,050 | $0.00 | $0 | 30,050 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | AGrant or award Restricted Share Unitderivative | +30,050 | $0.00 | $0 | 30,050 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | AGrant or award Share Optionderivative | +120,150 | $0.00 | $0 | 120,150 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | AGrant or award Share Optionderivative | +120,150 | $0.00 | $0 | 120,150 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative | -8,609 | $0.00 | $0 | 25,826 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative | -8,609 | $0.00 | $0 | 25,826 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative | -6,237 | $0.00 | $0 | 12,475 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative | -6,237 | $0.00 | $0 | 12,475 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative | -6,481 | $0.00 | $0 | 6,481 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative | -6,481 | $0.00 | $0 | 6,481 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative | -9,991 | $0.00 | $0 | 0 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative | -9,991 | $0.00 | $0 | 0 | 40 d ago |
| Nov 12, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | GGift Class A Ordinary Share | -111,794 | $0.00 | $0 | 0 | Nov 14, 2025 |
| Nov 12, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | GGift Class A Ordinary Shareindirect: Held by The Anglia 2013 Revocable Trust | +111,794 | $0.00 | $0 | 111,794 | Nov 14, 2025 |
| Nov 13, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | GGift Class A Ordinary Shareindirect: Held by The Anglia 2013 Revocable Trust | -60,000 | $0.00 | $0 | 51,794 | Nov 14, 2025 |
| Nov 13, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | GGift Class A Ordinary Shareindirect: Held by The Patel Family Irrevocable Trust of 2025 | +60,000 | $0.00 | $0 | 60,000 | Nov 14, 2025 |
| Oct 20, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +121,248 | $3.80 | $461k | 233,042 | Oct 22, 2025 |
| Oct 20, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | SOpen-market sale Class A Ordinary Share10b5-1 | -98,934 | $38.81 | $3.8M | 134,108 | Oct 22, 2025 |
| Oct 20, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | SOpen-market sale Class A Ordinary Share10b5-1 | -22,314 | $39.32 | $877k | 111,794 | Oct 22, 2025 |
| Oct 21, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +39,331 | $3.80 | $149k | 151,125 | Oct 22, 2025 |
| Oct 21, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | SOpen-market sale Class A Ordinary Share10b5-1 | -39,331 | $38.77 | $1.5M | 111,794 | Oct 22, 2025 |
| Oct 22, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +97,390 | $3.80 | $370k | 209,184 | Oct 22, 2025 |
| Oct 22, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | SOpen-market sale Class A Ordinary Share10b5-1 | -97,390 | $38.83 | $3.8M | 111,794 | Oct 22, 2025 |
| Oct 20, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Share Optionderivative10b5-1 | -121,248 | $0.00 | $0 | 136,721 | Oct 22, 2025 |
| Oct 21, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Share Optionderivative10b5-1 | -39,331 | $0.00 | $0 | 97,390 | Oct 22, 2025 |
| Oct 22, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Share Optionderivative10b5-1 | -97,390 | $0.00 | $0 | 0 | Oct 22, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share | +6,238 | - | - | 102,912 | Sep 3, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share | +6,481 | - | - | 109,393 | Sep 3, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share | +9,992 | - | - | 119,385 | Sep 3, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | FTax withholding Class A Ordinary Share | -10,983 | $33.49 | $368k | 108,402 | Sep 3, 2025 |
| Sep 2, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share | +6,569 | - | - | 114,971 | Sep 3, 2025 |
| Sep 2, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | FTax withholding Class A Ordinary Share | -3,177 | $34.28 | $109k | 111,794 | Sep 3, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | AGrant or award Restricted Share Unitderivative | +34,435 | $0.00 | $0 | 34,435 | Sep 3, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | AGrant or award Share Optionderivative | +137,638 | $0.00 | $0 | 137,638 | Sep 3, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative | -6,238 | $0.00 | $0 | 18,712 | Sep 3, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative | -6,481 | $0.00 | $0 | 12,962 | Sep 3, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative | -9,992 | $0.00 | $0 | 9,991 | Sep 3, 2025 |
| Sep 2, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative | -6,569 | $0.00 | $0 | 0 | Sep 3, 2025 |
| May 23, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +4,837 | $1.59 | $7,691 | 101,511 | May 28, 2025 |
| May 23, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | SOpen-market sale Class A Ordinary Share10b5-1 | -4,837 | $27.00 | $131k | 96,674 | May 28, 2025 |
50 of 94 rows shown.
Questions about Sanj K Patel
Answered from the filings on this page, as of the latest one.
Is Sanj K Patel buying or selling?
In the last 12 months Sanj K Patel reported 0 open-market buys worth $0 and 1 open-market sell worth $10M on SEC Form 4; the latest was sold $10M of KNSA on Oct 20, 2025. Grants, option exercises and tax withholding are not counted.
How did Sanj K Patel's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sanj K Patel has 0.
Where does Sanj K Patel file Form 4?
Sanj K Patel has filed Form 4 at KNSA (Kiniksa Pharmaceuticals International, plc) as CHAIRMAN & CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.